sck2 Antibody

What are the structural components of CK2 and which subunits can antibodies target?

CK2 exists predominantly as a tetrameric enzyme consisting of two catalytic subunits (α and/or α') and two regulatory (β) subunits. Researchers can obtain antibodies targeting specific subunits, including CK2α (encoded by the CSNK2A1 gene), CK2α' (encoded by CSNK2A2), and the regulatory CK2β subunit. Understanding the target epitope is crucial as different experimental applications may require antibodies recognizing distinct protein regions .

How should researchers select appropriate CK2 antibodies for specific experimental applications?

Selection should be based on the intended application. For Western blotting, antibodies recognizing denatured epitopes are suitable. For immunoprecipitation, antibodies must efficiently capture native protein complexes. For immunohistochemistry and immunofluorescence, antibodies must recognize epitopes accessible in fixed tissues or cells. Testing multiple antibodies targeting different epitopes is recommended to validate specificity. Recent characterization studies have evaluated commercial CSNK2A1 antibodies for Western blot, immunoprecipitation, and immunofluorescence applications using standardized protocols .

What expression systems can be used to validate CK2 antibody specificity?

The gold standard for antibody validation involves comparing signals between wild-type (WT) and knockout (KO) cells. HAP1 cell lines express CSNK2A1 at 7.0 log2 (TPM+1) RNA levels, making them suitable for antibody validation. Researchers should confirm target protein expression in their experimental system before proceeding with antibody-based studies .

What protocols maximize sensitivity and specificity in Western blot applications with CK2 antibodies?

For optimal Western blot results with CK2 antibodies, researchers should:

• Use appropriate positive controls (recombinant CK2 protein)

• Include negative controls (CK2 knockout cells where possible)

• Optimize antibody concentration through titration

• Use appropriate blocking solutions to reduce background

• Test multiple antibodies recognizing different epitopes to confirm specificity

Studies have demonstrated successful Western blot detection of CK2 subunits in various cell lines, with clear differentiation between wild-type and knockout samples .

How should immunoprecipitation experiments with CK2 antibodies be designed and validated?

For reliable immunoprecipitation results:

• Assess antibody capture capability by analyzing starting material (SM), unbound fraction (UB), and immunoprecipitate (IP) eluates

• Use a specific CK2 antibody previously validated by Western blot for detection

• Separate equal proportions of SM, UB, and IP by SDS-PAGE

• Include isotype-matched control antibodies to identify non-specific binding

• Consider native protein complex integrity when selecting lysis conditions

Experimental validation should compare immunoprecipitation efficiency between different antibodies to identify those with optimal capture capabilities .

What approaches ensure reliable immunofluorescence results with CK2 antibodies?

For immunofluorescence applications:

• Implement a mosaic strategy where WT and KO cells are labeled with distinct fluorescent dyes

• Image both cell types in the same field of view to reduce staining, imaging, and analysis bias

• Quantify immunofluorescence intensity across hundreds of cells for statistical robustness

• Test multiple antibody concentrations to determine optimal signal-to-noise ratio

• Use appropriate fixation methods (paraformaldehyde fixation has been validated for CK2 detection)

This approach enables objective assessment of antibody specificity and minimizes experimental artifacts .

How can CK2 antibodies be utilized to study disease-associated changes in CK2 expression?

CK2 antibodies can quantify changes in CK2 subunit expression in disease states. Studies have revealed increased CK2α protein expression in intestinal epithelial cells isolated from mouse models of chronic DSS colitis and bacterial colitis induced by Salmonella enterica. This approach involves:

• Isolating cells or tissues from disease and control samples

• Performing Western blot analysis with validated CK2 antibodies

• Quantifying relative protein expression levels

• Correlating protein changes with mRNA expression of corresponding genes (csnk2a1, csnk2a2, and csnk2b)

These techniques have successfully identified differential expression of CK2 subunits in pathological conditions .

What methods allow researchers to investigate CK2's role in cellular signaling pathways?

To study CK2's involvement in signaling pathways:

• Use CK2 antibodies to detect total and phosphorylated forms of CK2 and its substrates

• Combine antibody-based detection with pharmacological inhibitors (TBB, TBCA, emodin)

• Implement genetic approaches (siRNA knockdown) to validate inhibitor specificity

• Utilize reporter assays (e.g., TOPflash) to measure pathway activity

• Analyze phosphorylation of downstream targets (e.g., Akt at S129, β-catenin at S552)

Research has demonstrated CK2's role in promoting Wnt/β-catenin signaling and its connection to the Akt pathway in intestinal epithelial cells .

How can researchers use CK2 antibodies to investigate its anti-apoptotic functions?

To examine CK2's anti-apoptotic effects:

• Detect caspase activation (particularly caspase-9) using immunoblotting and immunostaining

• Compare apoptotic markers in cells with normal versus inhibited/depleted CK2

• Use antibodies to assess CK2-dependent phosphorylation events affecting cell survival

• Combine with functional assays (wound healing, cell migration) to connect molecular changes to cellular outcomes

Studies have demonstrated that CK2 inhibition increases caspase-9 activation and impairs epithelial restitution, highlighting CK2's role in promoting wound healing through apoptosis inhibition .

What are common pitfalls in CK2 antibody-based experiments and how can they be addressed?

Common challenges include:

For reliable results, researchers should validate antibodies in their specific experimental system rather than relying solely on manufacturer claims .

How should researchers approach antibody validation when knockout models aren't available?

When KO models are unavailable:

• Use siRNA or shRNA knockdown to create transient depletion models

• Compare multiple antibodies targeting different epitopes

• Include recombinant protein as a positive control

• Perform peptide competition assays with immunizing peptides

• Consider orthogonal methods (mass spectrometry) to confirm target identity

These approaches provide complementary evidence of antibody specificity when genetic knockout validation isn't possible .

What controls are essential when studying CK2 inhibition with antibody-based detection methods?

When using CK2 inhibitors alongside antibody detection:

• Include concentration gradients to establish dose-dependent effects

• Verify inhibitor specificity using antibodies against off-target kinases (e.g., GSK-3β)

• Compare pharmacological inhibition with genetic depletion approaches

• Monitor multiple downstream substrates to confirm pathway inhibition

• Include time-course experiments to distinguish direct from secondary effects

Studies have validated TBB, TBCA, and emodin as CK2 inhibitors at concentrations of 10-25μM without significant GSK-3β inhibition .

How are CK2 antibodies being applied to understand epithelial homeostasis mechanisms?

CK2 has been identified as a critical regulator of epithelial homeostasis in intestinal inflammation. Antibody-based studies have revealed:

• Increased CK2α expression in inflamed intestinal epithelium

• CK2's role in protecting intestinal epithelial cells from cytokine-induced apoptosis

• The importance of CK2 in promoting epithelial wound healing

• Mechanistic connections between CK2 activity and β-catenin stability

These findings highlight CK2 as a potential therapeutic target in inflammatory bowel diseases .

What methodological advances are improving monoclonal antibody generation against CK2 subunits?

Recent advances in monoclonal antibody production include:

• Use of bacterially expressed CK2β-6His-GST recombinant protein as antigen

• Immunization protocols with final boost strategies to enhance antibody titers

• Hybridoma generation using PEG 2000-mediated fusion with SP2/0 myeloma cells

• Selection in HAT-RPMI medium and subcloning by limiting dilution

• Multi-parameter testing across different applications (ELISA, Western blot, immunoprecipitation, immunohistochemistry)

These approaches have yielded antibodies specifically recognizing recombinant and endogenous CK2β subunits suitable for multiple applications .

How can researchers integrate CK2 antibody data with functional studies to understand biological significance?

To connect antibody-detected molecular changes with functional outcomes:

• Correlate CK2 expression/activity with cellular processes (proliferation, apoptosis, migration)

• Combine antibody detection with CK2 modulation (inhibitors, siRNA, overexpression)

• Use live cell imaging alongside fixed-cell antibody staining

• Implement rescue experiments to confirm specificity of observed effects

• Relate in vitro findings to in vivo disease models and human pathology samples

This integrated approach has successfully linked CK2 activity to intestinal epithelial homeostasis through mechanisms involving caspase-9 inhibition and β-catenin signaling .